Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in healthy participants and pulmonary arterial hypertension
NL-OMON61548Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of LTP001 in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability and Change in pulmonary vascular resistance. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON61548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61548.